[{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ CSL Vifor"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Medice Arzneimittel P\u00fctter GmbH&Co.KG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Medice Arzneimittel P\u00fctter GmbH&Co.KG"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"US Renal Care","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ US Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ US Renal Care"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Vifor Pharma"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Averoa","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"||Iron","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"||Phosphate","graph1":"Nephrology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"||Transferrin-1 receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"||Phosphate","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Termination","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Hematology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Citrate","moa":"||Transferrin-1 receptor","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Cyclerion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Praliciguat","moa":"||sGC","graph1":"Nephrology","graph2":"Phase II","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Akebia Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Akebia Therapeutics \/ Akebia Therapeutics"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Undisclosed","graph2":"Phase I","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Akebia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Hermann-Texas Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Akebia Therapeutics \/ Hermann-Texas Medical Center","highestDevelopmentStatusID":"5","companyTruncated":"Akebia Therapeutics \/ Hermann-Texas Medical Center"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"US Renal Care","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vadadustat","moa":"||HIF-PH","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akebia Therapeutics \/ US Renal Care","highestDevelopmentStatusID":"15","companyTruncated":"Akebia Therapeutics \/ US Renal Care"}]
Find Clinical Drug Pipeline Developments & Deals by Akebia Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
